251 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/353510/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-353510 Feb 11, 2019 - Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains http://www.zacks.com/stock/news/349681/4-toxic-stocks-to-get-rid-off-or-sell-short-for-solid-gains?cid=CS-ZC-FT-349681 Jan 25, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
INCY: Gabelli & Co ups to Buy http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190124085445 Jan 24, 2019 - Gabelli & Co issues rating change for INCY
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs http://www.zacks.com/stock/news/348985/biotech-stock-roundup-amgen-vertex-get-ec-nod-for-label-expansion-of-drugs?cid=CS-ZC-FT-348985 Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.
What's in Store for Merck in 2019 After a Solid Run in '18? http://www.zacks.com/stock/news/347164/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18?cid=CS-ZC-FT-347164 Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
4 Biotechs That Are Potential Buyouts Post Celgene Deal http://www.zacks.com/stock/news/346180/4-biotechs-that-are-potential-buyouts-post-celgene-deal?cid=CS-ZC-FT-346180 Jan 08, 2019 - We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan http://www.zacks.com/stock/news/345648/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan?cid=CS-ZC-FT-345648 Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review http://www.zacks.com/stock/news/344112/mercks-sbla-for-keytruda-in-lung-cancer-gets-extended-review?cid=CS-ZC-FT-344112 Dec 21, 2018 - FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY http://www.zacks.com/stock/news/343701/biotech-stock-roundup-pipeline-updates-from-vrtx-amgn-adro-teams-up-with-lly?cid=CS-ZC-FT-343701 Dec 19, 2018 - A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.

Pages: 12345678910...26

<<<Page 5>